The Hematologist

Ravindra Majeti, MD, PhD

Assistant Professor of Medicine
Division of Hematology, Stanford University School of Medicine
  • Pre-Leukemic Hematopoietic Stem Cells in Human Acute Myeloid LeukemiaJanuary 13, 2015 | January-February 2015, Volume 12, Issue 1

    Patients with de novo acute myeloid leukemia (AML) typically come to clinical attention with symptoms of bone marrow failure in the absence of any prior hematologic condition. In many such patients, the diagnosis is sudden and unexpected, without any significant prodrome. The generally poor prognosis of AML and the decades-long impasse in generating effective therapeutic strategies other than conventional antracycline and cytarabine-based (“3+7”) induction chemotherapy has spurred intense investigation of its molecular and cellular origins. Pioneering work by numerous investigators led to an early understanding of the genetics of AML, particularly the identification of recurrent chromosomal abnormalities and mutations in the genes FLT3 and NPM1. However, it is only with the recent implementation of massively parallel next-generation DNA sequencing that the full spectrum of mutations in AML has been defined.

back to top